317 related articles for article (PubMed ID: 21144842)
1. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
2. [Platinum agent-induced nephrotoxicity via organic cation transport system].
Yonezawa A
Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
4. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
Yokoo S; Yonezawa A; Masuda S; Fukatsu A; Katsura T; Inui K
Biochem Pharmacol; 2007 Aug; 74(3):477-87. PubMed ID: 17582384
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A).
Terada T; Inui K
Biochem Pharmacol; 2008 May; 75(9):1689-96. PubMed ID: 18262170
[TBL] [Abstract][Full Text] [Related]
6. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
8. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport.
Ludwig T; Riethmüller C; Gekle M; Schwerdt G; Oberleithner H
Kidney Int; 2004 Jul; 66(1):196-202. PubMed ID: 15200426
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
11. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
13. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
Yonezawa A; Masuda S; Nishihara K; Yano I; Katsura T; Inui K
Biochem Pharmacol; 2005 Dec; 70(12):1823-31. PubMed ID: 16242669
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
15. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
16. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
17. Saving ears and kidneys from cisplatin.
Wensing KU; Ciarimboli G
Anticancer Res; 2013 Oct; 33(10):4183-8. PubMed ID: 24122981
[TBL] [Abstract][Full Text] [Related]
18. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.
Liu JJ; Kim Y; Yan F; Ding Q; Ip V; Jong NN; Mercer JF; McKeage MJ
Biochem Pharmacol; 2013 Jan; 85(2):207-15. PubMed ID: 23123662
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
20. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
